Sugi Predict

Sugi Predict / Compounds / SCHEMBL725309

SCHEMBL725309

SCHEMBL725309

COc1ccc(C(=O)n2ccnc2-c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.53
▸ CNR2 P34972 1/20 0.50
▸ ALDH1A1 P00352 4/20 0.48
▸ CYP2C9 P11712 3/20 0.48
▸ HPGD P15428 2/20 0.48
▸ F2 P00734 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ TMIGD3 P0DMS9 1/20 0.47
▸ CES2 O00748 1/20 0.46
▸ CES1 P23141 1/20 0.46
▸ SLC6A7 Q99884 1/20 0.46
▸ BCHE P06276 2/20 0.46
▸ ACHE P22303 2/20 0.46
▸ KLK7 P49862 1/20 0.46
▸ KLK14 Q9P0G3 1/20 0.46
▸ KLK5 Q9Y337 1/20 0.46
▸ MAPK1 P28482 3/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL786746 0.87 ALDH1A1 (0.45) KMT2ACNR2ALDH1A1SLC6A7KLK7
SCHEMBL786798 0.85 ESR1 (0.50) KMT2AALDH1A1HPGDTMIGD3SLC6A7
SCHEMBL725082 0.81 THRB (0.53) KMT2AALDH1A1HPGDF2CYP1A2
SCHEMBL9880611 0.79 P2RX4 (0.48) KMT2AALDH1A1POLBLMNASMN1; SMN2
SCHEMBL16788608 0.79 MAPT (0.51) KMT2AALDH1A1HPGDCYP1A2BCHE
SCHEMBL28452609 0.75 KMT2A (0.52) KMT2ACNR2ALDH1A1HPGDSLC6A7
SCHEMBL28848047 0.74 ESR1 (0.54) KMT2AALDH1A1CYP1A2SMN1; SMN2KDR
SCHEMBL11078694 0.74 ESR1 (0.54) KMT2AALDH1A1CYP1A2SMN1; SMN2KDR
SCHEMBL10408730 0.73 FDPS (0.51) KMT2AALDH1A1CYP2C9HPGDSLC6A7
SCHEMBL10782342 0.73 ESR1 (0.50) KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 — — US disclosed
CN-119548495-A Use of (substituted 1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl) methanones for the treatment of coronaviruses 维鲁公司 2025-03-04 — — CN disclosed
EP-4504183-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS Veru Inc. (US) 2025-02-12 — — EP disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 — — US disclosed
CN-118984703-A Methods of treating influenza and poxvirus infections 维鲁公司 2024-11-19 — — CN disclosed
US-20240180879-A1 METHODS OF TREATING INFLAMMATION VERU INC. (US) 2024-06-06 — — US disclosed
EP-4320151-A1 METHODS OF TREATING INFLAMMATION Veru Inc. (US) 2024-02-14 — — EP disclosed
CN-117396505-A Methods of treating inflammation 维鲁公司 2024-01-12 — — CN disclosed
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — US disclosed
WO-2023196632-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — WO disclosed
US-9334242-B2 Compounds for treatment of cancer GTX, INC. (US) 2016-05-10 — — US disclosed
US-8822513-B2 Compounds for treatment of cancer GTX, INC. (US) 2014-09-02 — — US disclosed
WO-2012027481-A9 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2013-10-10 — — WO disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 — — US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 — — EP disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 — — EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 — — WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 KMT2A 2242/4885CNR2 3922/4885ALDH1A1 209/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 KMT2A 2242/4885CNR2 3922/4885ALDH1A1 209/4885
US-20240180879-A1 METHODS OF TREATING INFLAMMATION IL1B, PYCARD, TUBB1 KMT2A 3898/4885CNR2 1975/4885ALDH1A1 3707/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 KMT2A 2242/4885CNR2 3922/4885ALDH1A1 209/4885
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS TUBB3, TUBB1, TUBB KMT2A 3124/4885CNR2 4647/4885ALDH1A1 2765/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 KMT2A 2242/4885CNR2 3922/4885ALDH1A1 209/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 KMT2A 2242/4885CNR2 3922/4885ALDH1A1 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.